{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:28:16Z","timestamp":1790278096939,"version":"4.1.0"},"reference-count":31,"publisher":"PAGEPress Publications","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Histochem"],"abstract":"<jats:p>The therapeutic effects and potential mechanisms of astragaloside IV on a rabbits dry eye model induced by benzalkonium chloride (BAC) was examined. In our study, a BAC-induced dry eye rabbit model was treated with eye drops containing astragaloside IV (5, 10 \u03bcM) or solvent four times a day. The clinical evaluations, such as tear break-up time (BUT) and Schirmer tear test (STT), were performed on days 0, 7, 14, 21, and 28. On day 28, the cornea and bulbar conjunctiva tissues (left eye and right eye) were collected with histology, and immunofluorescent staining conducted. The levels of MUC1 and ErbB1in the corneas were determined by real-time quantitative PCR (qRT-PCR) and the proteins levels of MUC1 and ErbB1 were detected by Western blot. It was demonstrated that both astragaloside IV (5, 10 \u03bcM) treatments resulted in an increased STT and BUT on days 7, 14, 21 and 28. Additionally, the astragaloside IV (5, 10 \u03bcM)-treated group showed increasing PAS-positive goblet cells than model group (0 \u03bcM). Moreover, the MUC1 in model group (0 \u03bcM) was decreased, while the expression of MUC1 in astragaloside IV (5, 10 \u03bcM) group was increased. Furthermore, astragaloside IV had a protective effect on BAC-induced rabbits\u2019 dry eye and demonstrated clinical improvements, which indicated that astragaloside IV served as a potential protective agent in the clinical treatment of dry eye.<\/jats:p>","DOI":"10.4081\/ejh.2021.3198","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T10:58:45Z","timestamp":1617274725000},"source":"Crossref","is-referenced-by-count":8,"title":["Astragalus \u2163 ameliorates the dry eye injury in rabbit model &lt;em&gt;via&lt;\/em&gt; MUC1-ErbB1 pathway"],"prefix":"10.4081","volume":"65","author":[{"given":"Li","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-5626","authenticated-orcid":false,"given":"Wenfu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"573","doi-asserted-by":"crossref","unstructured":"Calonge M, Enr\u00edquez\u2013de\u2013Salamanca A, Diebold Y, Gonz\u00e1lez\u2013Garc\u00eda MJ, Reinoso R, Herreras JM, et al. Dry eye disease as an inflammatory disorder. Ocul Immunol Inflamm 2010;18:244-53.","DOI":"10.3109\/09273941003721926"},{"key":"574","doi-asserted-by":"crossref","unstructured":"Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. The TFOS dry eye workshop II: executive summary. Ocul Surf 2017;15:802-12.","DOI":"10.1016\/j.jtos.2017.08.003"},{"key":"575","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs I, Luna C, Quirce S, Mizerska K, Callejo G, Riestra A, et al. Abnormal activity of corneal cold thermoreceptors underlies the unpleasant sensations in dry eye disease. J Pain 2016;157:399-417.","DOI":"10.1097\/j.pain.0000000000000455"},{"key":"576","doi-asserted-by":"crossref","unstructured":"Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II definition and classification report. Ocul Surf 2017;15:276-83.","DOI":"10.1016\/j.jtos.2017.05.008"},{"key":"577","doi-asserted-by":"crossref","unstructured":"You H, Lu Y, Gui D, Peng A, Chen J, Gu Y. Aqueous extract of Astragali Radix ameliorates proteinuria in adriamycin nephropathy rats through inhibition of oxidative stress and endothelial nitric oxide synthase. J Ethnopharmacol 2011;134:176-82.","DOI":"10.1016\/j.jep.2010.11.064"},{"key":"578","doi-asserted-by":"crossref","unstructured":"Cheng X, Gu J, Zhang M, Yuan J, Zhao B, Jiang J, Ji X. Astragaloside IV inhibits migration and invasion in human lung cancer A549 cells via regulating PKC-\u03b1-ERK1\/2-NF-\u03baB pathway. Int J Immunopharmaco 2014;23:304-13.","DOI":"10.1016\/j.intimp.2014.08.027"},{"key":"579","doi-asserted-by":"crossref","unstructured":"Gui D, Huang J, Guo Y, Chen J, Chen Y, Xiao W, et al. astragaloside IV ameliorates renal injury in streptozotocin\u2013induced diabetic rats through inhibiting NF-\u03baB-mediated inflammatory genes expression. Cytokine 2013;61:970-7.","DOI":"10.1016\/j.cyto.2013.01.008"},{"key":"580","doi-asserted-by":"crossref","unstructured":"Zhang WJ, Hufnagl P, Binder BR, Wojta J. Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF\u2013\u03baB activation and adhesion molecule expression. Thromb Haemost 2003;89:904-14.","DOI":"10.1160\/TH03-03-0136"},{"key":"581","doi-asserted-by":"crossref","unstructured":"Schroeder JA, Thompson MC, Gardner MM, Gendler SJ. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen\u2013activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001;276:13057-64.","DOI":"10.1074\/jbc.M011248200"},{"key":"582","doi-asserted-by":"crossref","unstructured":"Imbert Y, Darling DS, Jumblatt MM, Foulks GN, Couzin EG, Steele PS, et al. MUC1 splice variants in human ocular surface tissues: possible differences between dry eye patients and normal controls. Exp Eye Res 2006;83:493-501.","DOI":"10.1016\/j.exer.2006.01.031"},{"key":"583","unstructured":"Inatomi T, Spurr-Michaud S, Tisdale AS, Zhan Q, Feldman ST, Gipson IK. Expression of secretory mucin genes by human conjunctival epithelia. Invest Ophth Vis Sci 1996;37:1684-92."},{"key":"584","doi-asserted-by":"crossref","unstructured":"Spicer AP, Parry G, Patton S, Gendler SJ. Molecular cloning and analysis of the mouse homologue of the tumor\u2013associated mucin, MUC1, reveals conservation of potential O\u2013glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite\u2013like polymorphism. J Biol Chem 1991;266:15099-109.","DOI":"10.1016\/S0021-9258(18)98592-3"},{"key":"585","doi-asserted-by":"crossref","unstructured":"Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu\/ErbB\u20102 and ErbB\u20103 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. Embo J 1999;18:2149-64.","DOI":"10.1093\/emboj\/18.8.2149"},{"key":"586","doi-asserted-by":"crossref","unstructured":"Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004;10:136-43.","DOI":"10.1158\/1078-0432.CCR-0373-3"},{"key":"587","doi-asserted-by":"crossref","unstructured":"Qi Y, Gao F, Hou L, Wan C. Anti\u2013inflammatory and immunostimulatory activities of astragaloside IVs. Am J Chinese Med 2017;45:1157-67.","DOI":"10.1142\/S0192415X1750063X"},{"key":"588","doi-asserted-by":"crossref","unstructured":"Yang J, Wang HX, Zhang YJ, Yang YH, Lu ML, Zhang J, et al. astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4\/NF-\u043aB signaling pathway in isoproterenol\u2013induced myocardial hypertrophy. J Ethnopharmacol 2013;150:1062-70.","DOI":"10.1016\/j.jep.2013.10.017"},{"key":"589","doi-asserted-by":"crossref","unstructured":"Zhou X, Sun X, Gong X, Yang Y, Chen C, Shan G, et al. astragaloside IV from Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting inflammation via TLR4\/NF-\u043aB in vivo and in vitro. Int Immunopharmacol 2017;42:18-24.","DOI":"10.1016\/j.intimp.2016.11.006"},{"key":"590","doi-asserted-by":"crossref","unstructured":"Zhang Z, Yang WZ, Zhu ZZ, Hu QQ, Chen YF, He H, et al. Therapeutic effects of topical doxycycline in a benzalkonium chloride-induced mouse dry eye model. Invest Ophth Vis Sci 2014;55:2963-74.","DOI":"10.1167\/iovs.13-13577"},{"key":"591","doi-asserted-by":"crossref","unstructured":"Toshida H, Nguyen DH, Beuerman RW, Murakami A. Neurologic evaluation of acute lacrimomimetic effect of cyclosporine in an experimental rabbit dry eye model. Invest Ophth Vis Sci 2009;50:2736-41.","DOI":"10.1167\/iovs.08-1880"},{"key":"592","doi-asserted-by":"crossref","unstructured":"Oh JY, In YS, Kim MK, Ko JH, Lee HJ, Shin KC, et.al. Protective effect of uridine on cornea in a rabbit dry eye model. Invest Ophth Vis Sci 2007;48:1102-9.","DOI":"10.1167\/iovs.06-0809"},{"key":"593","doi-asserted-by":"crossref","unstructured":"Gipson IK. Distribution of mucins at the ocular surface. Exp Eye Res 2004;78:379-88.","DOI":"10.1016\/S0014-4835(03)00204-5"},{"key":"594","doi-asserted-by":"crossref","unstructured":"Gipson IK, Argueso P. Role of mucins in the function of the corneal and conjunctival epithelia. Int Rev Cytol 2003;231:1-49.","DOI":"10.1016\/S0074-7696(03)31001-0"},{"key":"595","doi-asserted-by":"crossref","unstructured":"Watanabe H. Significance of mucin on the ocular surface. Cornea 2002;21:S17-22.","DOI":"10.1097\/00003226-200203001-00005"},{"key":"596","doi-asserted-by":"crossref","unstructured":"Baudouin C, Rolando M, Del Castillo JMB, Messmer EM, Figueiredo FC, Irkec M, et al. Reconsidering the central role of mucins in dry eye and ocular surface diseases. Prog Retin Eye Res 2019;71:68-87.","DOI":"10.1016\/j.preteyeres.2018.11.007"},{"key":"597","doi-asserted-by":"crossref","unstructured":"Johnson ME, Murphy PJ. Changes in the tear film and ocular surface from dry eye syndrome. Prog Retin Eye Res 2004;23:449-74.","DOI":"10.1016\/j.preteyeres.2004.04.003"},{"key":"598","doi-asserted-by":"crossref","unstructured":"Albietz JM. Dry eye: an update on clinical diagnosis, management and promising new treatments. Clin Exp Optom 2001;84:4-18.","DOI":"10.1111\/j.1444-0938.2001.tb04930.x"},{"key":"599","doi-asserted-by":"crossref","unstructured":"Zhang X, Qu Y, He X, Ou S, Bu J, Jia C, et.al. Dry eye management: targeting the ocular surface microenvironment. Int J Mol Sci 2017;18:1398.","DOI":"10.3390\/ijms18071398"},{"key":"600","doi-asserted-by":"crossref","unstructured":"Wolosin JM, Budak MT, Akinci MAM. Ocular surface epithelial and stem cell development. Int J Dev Biol 2004;48:981-91.","DOI":"10.1387\/ijdb.041876jw"},{"key":"601","doi-asserted-by":"crossref","unstructured":"Carraway KL, Ramsauer VP, Haq B, Carothers Carraway CA. Cell signaling through membrane mucins. Bioessays 2003;25:66-71.","DOI":"10.1002\/bies.10201"},{"key":"602","unstructured":"Li Y, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, et al. Heregulin targets \u03b3-catenin to the nucleolus by a mechanism dependent on the DF3\/MUC1 oncoprotein. Mol Cancer Res 2003;1:765-75."},{"key":"603","doi-asserted-by":"crossref","unstructured":"Muraoka-Cook RS, Feng SM, Strunk KE, Earp HS. ErbB4\/HER4: role in mammary gland development, differentiation and growth inhibition. J Mammary Gland Biol Neoplasia 2008;13:235-46.","DOI":"10.1007\/s10911-008-9080-x"}],"container-title":["European Journal of Histochemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.ejh.it\/index.php\/ejh\/article\/download\/3198\/3101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejh.it\/index.php\/ejh\/article\/download\/3198\/3101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T10:59:16Z","timestamp":1617274756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejh.it\/index.php\/ejh\/article\/view\/3198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,3,24]]}},"URL":"https:\/\/doi.org\/10.4081\/ejh.2021.3198","relation":{},"ISSN":["2038-8306","1121-760X"],"issn-type":[{"value":"2038-8306","type":"electronic"},{"value":"1121-760X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}